Boston Scientific Announces Positive Late-Breaking Data From The INTREPID Study

MARLBOROUGH, Mass., April 24, 2018 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) today announced one-year data from the INTREPID study, the first and only prospective, double-blind, randomized, sham-controlled, mul... Devices, Neurology Boston Scientific, INTREPID study, deep brain stimulation, Parkinson's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news